hC5AR1/C5AR2

Nomenclature

C57BL/6Smoc-C5ar1tm1(hC5AR1)C5ar2tm1(hC5AR2)/Smoc

Cat. NO.

NM-HU-2000018

Strain State

Embryo cryopreservation

Export PDF

Model Description

The endogenous mouse C5ar1 and C5ar2 gene was replaced by human C5AR1 and hC5AR2 gene.
Research Application:Immunotherapy,drug screening

Validation Data

image.png

Fig1. Detection of C5AR1 and C5AR2 expression in spleen by RT-PCR. 

Wild type: only one band at 257 bp with primers F1/R1 (mC5ar1), only one band at 506 bp with primers F3/R3 (mC5ar2);

Homozygous: only one band at 313 bp with primers F2/R2 (hC5AR1),  only one band at 318 bp with primers F4/R4 (hC5AR2).

Abbr. M, DNA marker; HO, homozygous; WT, wild type.image.png

Fig2. Detection of C5AR1 expression on myeloid cells in blood in hC5AR1 knockin mice.

image.png

Fig3. Detection of C5AR1 expression on myeloid cells in bone morrow in hC5AR1 knockin mice.

image.png

Fig4. Detection of C5AR2 expression on myeloid cells in spleen in hC5AR1/hC5AR2 dKI mice. (Note: Anti-human C5L2 (C5AR2) antibody was cross-binding with mouse C5AR2)

image.png

Fig5. Detection of C5AR2 expression on myeloid cells in bone marrow in hC5AR1/hC5AR2 dKI mice. (Note: Anti-human C5L2 (C5AR2) antibody was cross-binding with mouse C5AR2)

image.png

Fig6. Detection of hC5AR2 expression on myeloid cells in peritoneal lavage fluids in hC5AR1/hC5AR2 dKI mice. (Note: Anti-human C5L2 (C5AR2) antibody was cross-binding with mouse C5AR2)


You may also like

Shanghai Model Organisms Center Inc has licensed CRISPR-Cas9 technology from Broad Institute

On Dec 16, 2018, Broad Institute and Shanghai Model Organisms Center Inc (SMOC) has entered into a non-exclusive license agreement under which Broad has granted SMOC worldwide rights to commercialize a service platform for genetically modified mouse models under Broad's intellectual property.

Learn more
Workshop:Progress and Advances in Preclinical immuno-Oncology Research

SMOC’s Annual Progress and Advances in Preclinical immuno-Oncology Research: The workshop is designed as a forum for ideas and opinions exchange on how to decrease the rate of clinical failures in oncology and immuno-oncology.

Learn more